However, this approval is subject to the condition that the firm should conduct a Phase IV clinical trial and be required to submit the Phase IV clinical trial protocol to CDSCO within 03 months from the date of approval.
This came after the drug maker Eli Lilly presented the proposal for import and marketing permission of Tirzepatide 2.5 mg/0.5 ml, 5mg/0.5ml, 10mg/0.5 ml, 12.5 mg/0.5 ml and 15mg/.5 ml solution for injection (Single dose vial) along with their justification for bioequivalence (BE) and clinical trial (CT) waiver before the committee.
The firm informed that a similar formulation i.e Tirzepatide 2.5 mg/0.5 ml, 5mg/0.5ml, 10mg/0.5 ml, 12.5 mg/0.5 ml, and 15mg/.5 ml injection in the prefilled pen is already approved by the CDSCO for the same indication and now the firm has proposed for formulation in a single-dose vial presentation.
Tirzepatide is a dual GIP and GLP-1 receptor agonist used for the treatment of type II diabetes in adults as an adjunct to diet and exercise.
Tirzepatide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus or for chronic weight management for adult patients that are obese or overweight with at least one weight-related comorbid condition such as hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea, or cardiovascular disease).
Tirzepatide is a peptide molecule that acts as a dual agonist at GLP-1 and GIP receptors. It enhances the insulin response, suppresses glucagon secretion, promotes satiety, and improves insulin sensitivity.
At the recent SEC meeting for Endocrinology and Metabolism held on 13th and 14th February 2023, the expert panel reviewed the proposal for import and marketing permission of Tirzepatide along with their justification for BE and CT waiver.
After detailed deliberation, the committee recommended the import and marketing permission of Tirzepatide 2.5 mg/0.5 ml, 5mg/0.5ml, 10mg/0.5 ml, 12.5 mg/0.5 ml, and 15mg/.5 ml solution for injection (single dose vial) subject to the condition that the firm should conduct Phase-IV clinical trial.
Accordingly, the expert panel suggested that the firm should submit a Phase-IV clinical trial protocol to CDSCO within 03 months from the date of approval for further review by the committee.
Furthermore, the committee opined that the firm should fulfill the requirement of chemistry, manufacturing, and controls (CMC) data along with comparative data with that of the already approved pre-filled pen.
Also Read:Glenmark Gets CDSCO Panel Nod to Study ISB 2001 in Multiple Myeloma
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.